Navigation Links
InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
Date:6/29/2010

sensitization is a core therapeutic mechanism for addressing the Type 2 Diabetes epidemic," added Dr. Linda Higgins, President & Chief Operating Officer of InteKrin Therapeutics. "INT131 besylate offers a potential significant advance in addressing the critical need for a safe insulin sensitizer."

About INT131:

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of Type 2 Diabetes. As a selective PPAR-gamma modulator (SPPARM), INT131 has been designed to provide potent glucose lowering and durability of effect without the recognized side effects of the currently available insulin sensitizers which, unlike INT131, are full PPAR-gamma agonists. InteKrin has completed an End-Of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for INT131 and is moving the program into Phase 3 development.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clini
'/>"/>

SOURCE InteKrin Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
5. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
6. InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  Legal-Bay LLC, The Lawsuit ... Boehringer Ingelheim Pharmaceuticals, is seeking FDA approval for ... According to PBR, Boehringer submitted a supplemental new ... that Pradaxa will be approved for the prophylaxis ... (PE) for patients who have undergone a primary ...
(Date:4/20/2015)... is the daily "Profile America" feature from the U.S. ... Profile America — Tuesday, April 21st. One ... for general use this month in 1923, saving the ... is a hormone produced by the pancreas and is ... body. It was first isolated the year before by ...
(Date:4/20/2015)... Gregory Taylor , Canada,s Chief Public Health ... a week in West Africa . The visit ... the ground as global efforts continue to reach zero Ebola cases. ... in Sierra Leone and Guinea ... work being done and hear from those on the front-lines about ...
Breaking Medicine Technology:Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 2Pradaxa Maker Boehringer Ingelheim Pharmaceuticals Pursues Pradaxa FDA Approval to treat DVT and PE 3U.S. Census Bureau Daily Feature for April 21 2Canada's Efforts Making a Difference in the Fight Against Ebola 2Canada's Efforts Making a Difference in the Fight Against Ebola 3Canada's Efforts Making a Difference in the Fight Against Ebola 4Canada's Efforts Making a Difference in the Fight Against Ebola 5
... and CARLSBAD, Calif., Aug. 6 ,Genzyme Corp. (Nasdaq: ... ),today announced that they have begun a phase 3 ... a genetic,disorder that causes exceptionally high levels of LDL ... companies plan to initiate by the end of,this year, ...
... the most recent issue of,Optometry & Vision Development, two ... Fischer and his team which found,that children with vision ... that if the appropriate vision therapy is given,math skills ... several German television news,programs which reported on his research ...
Cached Medicine Technology:Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 2Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 3Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 4Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 5Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 6Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen 7Vision Problems Affect How Children Learn Math Skills 2
(Date:4/21/2015)... On Saturday, May 2nd, 2015, board certified ophthalmologist ... from Georgia Eye Physicians and Surgeons will ... held in Piedmont Park by the Lupus Foundation of ... largest LFA-sponsored walk in the nation, hosting more than ... awareness for lupus, an unpredictable and potentially fatal autoimmune ...
(Date:4/21/2015)... Antonio, TX (PRWEB) April 21, 2015 ... rights from a prestigious Illinois university for a ... care units (NICUs) more conducive to newborn infants’ ... the top three NICU problems we have identified ... neonatal care professionals,” said George Hutchinson, Invictus Medical’s ...
(Date:4/21/2015)... 2015 “The warm summer season is fast ... want to look younger than her age? In the ... of defense. Signs of premature aging are deep ... too much time spent in the sun without adequate protection.” ... up. The dangers of UV rays can go deep ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Heritage Woods ... host an Open House and Dine-and-Dash Spaghetti Dinner from ... The community, which is located in Centralia, Illinois, houses ... homes for low-income adults 55 and older. , Guests ... staff about supportive living options for seniors. After the ...
(Date:4/20/2015)... (PRWEB) April 21, 2015 Using Quality ... CMOs Speed Production and Improve Compliance , **FDAnews Webinar**, ... EDT, http://www.fdanews.com/qualitybydesign , The life sciences industries ... them to do more with less. Mergers, acquisitions, ... CMOs to finds ways to speed up production while ...
Breaking Medicine News(10 mins):Health News:9th Annual Walk to End Lupus Now 2Health News:9th Annual Walk to End Lupus Now 3Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 3
... from various poultry farms across the state of Chattisgarh ... ,"Chhattisgasrh has not a single bird flu case ... at the High Security Animal Disease Lab at Bhopal," ... ,An official statement Thursday said the state government had ...
... Online counseling through Internet is gaining momentum slowly but surely ... practitioner// and discuss problems of any sort, as they do ... ,If the person being talked to is not visible, it ... or problems. ,"Psychotherapy is treatment for mental or ...
... Centers for Disease Control and Prevention highlights that very ... and contradicts the widely held public perception which blames ... ,The study for the first time challenges the ... HIV/AIDS, among the Blacks. The researchers of the present ...
... has caused the health officials to request the airlines ... Disease Control and Prevention have asked them to collect ... contact numbers and detailed flight information, to help track ... an additional expenditure on the airlines which is already ...
... various organizations are putting in their effort to combat the ... of the disease from the face of the earth. One ... India, and asked all the non-governmental organizations (NGOs) who are ... work as a unit. It asked them to co operate ...
... U.S. Army Medical Research Institute of Infectious Diseases and ... of Canada reported yesterday that the vaccine that is ... in monkeys after they were exposed to the deadly ... for the infection caused by Ebola virus. ...
Cached Medicine News:Health News:Anonymity Helps In Overcoming Inhibitions During Online Counseling 2Health News:New Vaccine To Combat The Deadly Marburg Virus 2
... The Laserex Ultra Q is the fundamental ... cavity optimizes energy delivery and provides 2855% less ... to 2.54.0 mJs in contemporary systems. This ... dramatically reduces the risk of IOL pitting. ...
... Ultrasonix 500 is a high-end, mobile ultrasound ... architecture provides a tremendous amount of processing ... and resolution. Ultrasonix imaging systems provide ... including B, B/M, Pulsed Doppler, Color Doppler ...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
Medicine Products: